As the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% seroconverted, with significantly lower seroconversion rates in those over 60 years (p = 0.004) and significantly lower than previously seen with AZD1222 (p = 0.018). 82.6% developed ACE2 receptor blocking antibodies, although levels were significantly lower than following natural infection (p = 0.0009) and a single dose of AZD1222 (p
Journal article
Sci Rep
02/02/2022
12
Adult, Aged, Aged, 80 and over, Angiotensin-Converting Enzyme 2, Antibodies, Neutralizing, Antibodies, Viral, Biomarkers, COVID-19, COVID-19 Vaccines, ChAdOx1 nCoV-19, Female, Humans, Immunization, Immunogenicity, Vaccine, Interferon-gamma, Lymphocytes, Male, Middle Aged, SARS-CoV-2, Seroconversion, Time Factors, Treatment Outcome, Vaccines, Synthetic, Young Adult